Literature DB >> 34127042

Recruitment and retention rates in randomised controlled trials of exercise therapy in people with multimorbidity: a systematic review and meta-analysis.

Lasse K Harris1,2, Søren T Skou3,4, Carsten B Juhl3,5, Madalina Jäger3,4, Alessio Bricca3,4.   

Abstract

AIM: To quantify recruitment, retention and differential retention rates and associated trial, participant and intervention characteristics in randomised controlled trials (RCTs) evaluating the effect of exercise therapy in people with multimorbidity. DATA SOURCES: MEDLINE, EMBASE, CINAHL and CENTRAL from 1990 to April 20, 2020. STUDY SELECTION: RCTs including people with multimorbidity comparing exercise therapy with a non-exposed comparator group reporting at least one of the following outcomes: physical function, health-related quality of life, depression symptoms, or anxiety symptoms. DATA EXTRACTION AND SYNTHESIS: Recruitment rates (proportion of people randomised/proportion of people eligible), retention rates (proportion of people providing the outcomes of interest/proportion randomised) and differential retention rates (difference in proportion of people providing the outcomes in the intervention group and comparator group) were calculated. Meta-analysis using a random-effects model was used to estimate pooled proportions. Methodological quality was assessed using Cochrane ´Risk of Bias tool 2.0´ for individual studies, and the GRADE approach was used to assess the overall quality of the evidence.
RESULTS: Twenty-three RCTs with 3363 people were included. The pooled prevalence for recruitment rate was 75% (95%CI 66 to 84%). The pooled prevalence for retention rate was 90% (95%CI 86 to 94%) at the end of the intervention (12 weeks; interquartile range (IQR) (12 to 12)). Meta-regression analyses showed that increasing age and including a higher proportion of people with hypertension was associated with lower retention rates. Retention rates did not differ between the intervention and comparator groups. The overall quality of the evidence was deemed very low.
CONCLUSION: Three in four eligible people with multimorbidity were randomised to RCTs using exercise therapy, of which nine out of 10 provided end of treatment outcomes with no difference seen between the intervention and comparison groups. However, the results must be interpreted with caution due to large differences between the included studies. TRIAL REGISTRATION: ClinicalTrials.gov CRD42020161329 . Registered on 28 April 2020.

Entities:  

Keywords:  Exercise therapy; Multimorbidity; Randomised controlled trial; Recruitment; Retention; Systematic review

Mesh:

Year:  2021        PMID: 34127042     DOI: 10.1186/s13063-021-05346-x

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  30 in total

1.  How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?

Authors:  Mary S Fewtrell; Kathy Kennedy; Atul Singhal; Richard M Martin; Andy Ness; Mijna Hadders-Algra; Berthold Koletzko; Alan Lucas
Journal:  Arch Dis Child       Date:  2008-06       Impact factor: 3.791

2.  The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease.

Authors:  Michael Gleeson; Nicolette C Bishop; David J Stensel; Martin R Lindley; Sarabjit S Mastana; Myra A Nimmo
Journal:  Nat Rev Immunol       Date:  2011-08-05       Impact factor: 53.106

3.  Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research.

Authors:  C J Caspersen; K E Powell; G M Christenson
Journal:  Public Health Rep       Date:  1985 Mar-Apr       Impact factor: 2.792

4.  Osteoarthritis of the hip or knee: which coexisting disorders are disabling?

Authors:  Kerstin G Reeuwijk; Mariëtte de Rooij; Gabriella M van Dijk; Cindy Veenhof; Martijn P Steultjens; Joost Dekker
Journal:  Clin Rheumatol       Date:  2010-02-23       Impact factor: 2.980

5.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

6.  Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study.

Authors:  G E Caughey; E N Ramsay; A I Vitry; A L Gilbert; M A Luszcz; P Ryan; E E Roughead
Journal:  J Epidemiol Community Health       Date:  2009-10-23       Impact factor: 3.710

7.  Descriptions of barriers to self-care by persons with comorbid chronic diseases.

Authors:  Elizabeth A Bayliss; John F Steiner; Douglas H Fernald; Lori A Crane; Deborah S Main
Journal:  Ann Fam Med       Date:  2003 May-Jun       Impact factor: 5.166

8.  The increasing burden and complexity of multimorbidity.

Authors:  Anna J Koné Pefoyo; Susan E Bronskill; Andrea Gruneir; Andrew Calzavara; Kednapa Thavorn; Yelena Petrosyan; Colleen J Maxwell; YuQing Bai; Walter P Wodchis
Journal:  BMC Public Health       Date:  2015-04-23       Impact factor: 3.295

9.  GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research.

Authors:  Carol Sinnott; Sheena Mc Hugh; John Browne; Colin Bradley
Journal:  BMJ Open       Date:  2013-09-13       Impact factor: 2.692

10.  Patient-centered recruitment and retention for a randomized controlled study.

Authors:  Sumedha Chhatre; Ashlie Jefferson; Ratna Cook; Caitlin R Meeker; Ji Hyun Kim; Kayla Marie Hartz; Yu-Ning Wong; Adele Caruso; Diane K Newman; Knashawn H Morales; Ravishankar Jayadevappa
Journal:  Trials       Date:  2018-03-27       Impact factor: 2.279

View more
  1 in total

Review 1.  Retention in RCTs of physical rehabilitation for adults with frailty: a systematic review and meta-analysis.

Authors:  Heather K O'Grady; Christopher Farley; Alyson Takaoka; Elisa Mayens; Jackie Bosch; Lyn Turkstra; Michelle E Kho
Journal:  Trials       Date:  2022-03-28       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.